Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🚫 This provider appears on the OIG List of Excluded Individuals/Entities (LEIE)
Exclusion type: 1128(b)(4) — License Revocation/Suspension · Date: 07/20/2025 · State: TX
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
39,453
Total Claims
$7.8M
Drug Cost
1,268
Beneficiaries
$6,112
Cost/Patient
Risk Score Breakdown 51/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+295%
Opioid rate vs peers
8.8% vs 2.2% avg
+333%
Cost per patient vs peers
$6,112 vs $1,411 avg
+40%
Brand preference vs peers
14.9% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider appears on the federal OIG exclusion list, meaning they have been formally barred from participating in federal healthcare programs due to fraud, patient abuse, licensing issues, or other misconduct. The fact that they still appear in active prescribing data is a significant concern.
Opioid rate is 295% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Composite risk score of 51/100 places this provider in the "High Risk" category — the top 0.017% of all Medicare Part D prescribers. Multiple independent risk factors are contributing simultaneously.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
8.8%
Opioid Rate
3,491
Opioid Claims
$124K
Opioid Cost
0.9%
Long-Acting Rate
Brand vs Generic
Brand: 5,778 claims · $5.8M
Generic: 33,097 claims · $1.9M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 474 | $759K |
| Deutetrabenazine | 95 | $709K |
| Fluticasone/Umeclidin/Vilanter | 354 | $485K |
| Apixaban | 306 | $320K |
| Budesonide/Formoterol Fumarate | 313 | $224K |
| Bictegrav/Emtricit/Tenofov Ala | 49 | $201K |
| Linaclotide | 188 | $177K |
| Paliperidone Palmitate | 33 | $142K |
| Metformin Hcl | 14 | $122K |
| Abacavir/Dolutegravir/Lamivudi | 29 | $112K |
| Sitagliptin Phosphate | 88 | $92K |
| Sevelamer Carbonate | 61 | $85K |
| Insulin Detemir | 101 | $84K |
| Hydrocodone/Acetaminophen | 2,241 | $82K |
| Adalimumab | 11 | $81K |
Prescribing Profile
Patient Profile
65
Avg Age
53%
Female
2.77
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data